<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="radiology" lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher">JOHS</journal-id>
<journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id>
<journal-title-group>
<journal-title>Journal of HealthCare Sciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">2231-2196</issn>
<issn pub-type="opub">0975-5241</issn>
<publisher>
<publisher-name>Radiance Research Academy</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">535</article-id>
<article-id pub-id-type="doi">http://dx.doi.org/10.52533/JOHS.2026.60607</article-id>
<article-id pub-id-type="doi-url"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Radiology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neuroimaging Patterns in Substance-Induced Psychotic Disorders
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ahmad</surname>
<given-names>Doha Jamal</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alhasan</surname>
<given-names>Sara Ali</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aldallal</surname>
<given-names>Khadija Mohamed</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alshammari</surname>
<given-names>Mariam Hadi</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>AlRshood</surname>
<given-names>Abdullah Rshood</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alyami</surname>
<given-names>Ali Hadi</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alshammari</surname>
<given-names>Bader Hadi</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alrowili</surname>
<given-names>Faisal Mansour</given-names>
</name>
</contrib>
</contrib-group>
<pub-date pub-type="ppub">
<day>14</day>
<month>06</month>
<year>2026</year>
</pub-date>
<volume>6</volume>
<issue>6</issue>
<fpage>367</fpage>
<lpage>373</lpage>
<permissions>
<copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement>
<copyright-year>2009</copyright-year>
<license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract>
<p>Substance-induced psychotic disorder (SIPD) is a clinically significant condition characterized by the emergence of psychotic symptoms following the use, intoxication, or withdrawal of psychoactive substances. The increasing prevalence of substance use worldwide, coupled with the growing recognition of psychosis as a severe neuropsychiatric consequence of substance exposure, has intensified interest in understanding the underlying neurobiological mechanisms of the disorder. Neuroimaging has become a valuable tool for investigating structural, functional, and neurochemical abnormalities that may contribute to symptom development. Evidence from magnetic resonance imaging (MRI), functional MRI, diffusion tensor imaging, positron emission tomography, and single-photon emission computed tomography has identified abnormalities in several brain regions involved in cognition, emotional regulation, salience attribution, and reward processing. Frequently implicated areas include the prefrontal cortex, hippocampus, amygdala, thalamus, and striatum. Structural imaging studies have demonstrated alterations in gray matter volume and white matter integrity, while functional imaging has revealed disruptions in neural connectivity and network organization. Molecular imaging findings have highlighted disturbances in dopaminergic and other neurotransmitter systems that parallel mechanisms observed in primary psychotic disorders. Neuroimaging data also suggest the presence of substance-specific patterns of brain dysfunction. Psychosis associated with methamphetamine use is commonly linked to frontostriatal abnormalities and dopaminergic dysregulation, whereas cannabis-related psychosis has been associated with hippocampal and cortical alterations. Despite considerable overlap with schizophrenia-spectrum disorders, distinct imaging profiles may exist that reflect the neurobiological effects of different substances. The identification of reliable neuroimaging biomarkers remains challenging due to methodological heterogeneity, variations in substance exposure, and the complex interaction between substance-related effects and underlying vulnerability to psychosis. Nevertheless, advances in multimodal imaging and computational analysis continue to improve our understanding of SIPD and may facilitate more accurate diagnosis, risk stratification, and treatment planning.
</p>
</abstract>
<kwd-group>
<kwd>substance-induced psychotic disorder</kwd>
<kwd> neuroimaging</kwd>
<kwd> magnetic resonance imaging</kwd>
<kwd> positron emission tomography</kwd>
<kwd> psychosis biomarkers</kwd>
</kwd-group>
</article-meta>
</front>
</article>